Urgent

Wilson's disease

Hepatolenticular degeneration · Neurology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

An autosomal recessive disorder of copper metabolism causing hepatic and neuropsychiatric disease, typically in young adults, with movement disorder, dysarthria and Kayser-Fleischer rings. Treatable and reversible if recognised early, so should be excluded in any young patient with movement disorder or unexplained liver disease.

Red flags

  • Acute liver failure (coagulopathy, encephalopathy) - transplant emergency
  • Neurological deterioration on starting chelation
  • Haemolytic anaemia
  • Severe psychiatric disturbance
  • Non-adherence with therapy

Assessment

Differential diagnosis

  • Other young-onset movement disorders (dystonia, parkinsonism, tremor)
  • Huntington's disease
  • Primary psychiatric disorder
  • Autoimmune or viral hepatitis
  • Drug-induced parkinsonism
  • Acquired hepatocerebral degeneration

Investigations

  • Serum caeruloplasmin (low) and serum copper
  • 24-hour urinary copper (elevated, rises further after penicillamine challenge)
  • Slit-lamp examination for Kayser-Fleischer rings
  • MRI brain (basal ganglia/midbrain signal change, face of the giant panda sign)
  • Liver function tests and liver synthetic function
  • ATP7B genetic testing; liver biopsy copper quantification if uncertain

Management

  • Suspect Wilson's in any young patient with movement disorder, unexplained liver disease or psychiatric change
  • Screen with caeruloplasmin, 24-hour urinary copper and slit-lamp examination
  • Confirm with genetic testing or hepatic copper quantification
  • Assess hepatic and neurological severity and screen first-degree relatives
  • Start copper-chelation or zinc therapy promptly
  • Introduce chelators cautiously as neurological worsening can occur initially
  • Advise a low-copper diet (avoid shellfish, liver, nuts, chocolate)
  • Treat psychiatric and movement symptoms symptomatically
  • Monitor copper indices, liver and blood counts during therapy
  • Refer fulminant hepatic failure for urgent transplant assessment

Drugs & doses

Penicillamine 250 mg PO daily titrated to 1-1.5 g/day in divided doses (with pyridoxine 25 mg daily)
Trientine 300 mg PO TDS-QDS as alternative chelator (better tolerated)
Zinc acetate 50 mg PO TDS (maintenance or first-line in neurological disease)
Avoid copper-rich foods
Tetrahydromolybdate (specialist, where available) for neurological disease

Disposition

Specialist hepatology-neurology service. Lifelong treatment and monitoring. Urgent transplant referral for acute liver failure. Screen relatives.

Complications & pitfalls

  • Cirrhosis and fulminant hepatic failure
  • Irreversible neurological disability if untreated
  • Paradoxical neurological worsening with penicillamine
  • Haemolytic crises
  • Treatment non-adherence relapse

Exam pearls

  • Always exclude Wilson's in a young person with new movement disorder or unexplained liver disease
  • Kayser-Fleischer rings are usually present when neurological features exist
  • Penicillamine can transiently worsen neurology; some start zinc or trientine in neurological disease
  • It is one of the few genuinely treatable neurodegenerative disorders if caught early

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.